Dicerna Pharmaceuticals Inc DRNA, a biotechnology company developing GalXC RNAi platforms for various diseases, has seen its stock soar 140 percent over the past six months. But a combination of good news and bad news should leave investors on the sidelines, according to B. Riley FBR. The Analyst B Riley FBR's Madhu Kumar initiated coverage of Dicerna Pharmaceuticals' stock with a Neutral rating and $10 price target. SourceStichastics are oversold. We can expect a breakout and some upside. $DRNA, Dicerna Pharmaceuticals, Inc. / D